Form 4: Sutro Biopharma Director Granted Stock Options
Insider Transaction Report
Sutro Biopharma director James P. Panek received a grant of 1,500 stock options with an exercise price of $10.38, vesting monthly over approximately six months.
Summary
- James P. Panek, a Director of Sutro Biopharma, Inc. (STRO), was granted 1,500 stock options.
- The options have an exercise price of $10.38 per share.
- The grant date for these options was December 23, 2025.
- The options will vest at a rate of 16.67% of the total award monthly, contingent on Mr. Panek's continued service to the company.
- The first vesting tranche is scheduled for January 23, 2026, completing the vesting over approximately six months.
- The options have an expiration date of December 23, 2035.
- Following this transaction, Mr. Panek beneficially owns 1,500 derivative securities directly.
Sentiment
Score: 6
Explanation: The grant of stock options to a director is a standard compensation practice, generally viewed as a neutral to slightly positive event as it aligns the director's interests with the company's long-term performance. It does not indicate any immediate operational or financial changes.
Positives
- The grant of stock options aligns the director's interests with long-term shareholder value.
- The vesting schedule incentivizes continued service and commitment from the director.
Future Outlook
The stock options granted to Director James P. Panek are structured with a monthly vesting schedule, beginning January 23, 2026, and completing over approximately six months, expiring on December 23, 2035. This indicates a short-term incentive for his continued service to secure the full grant, while the long expiration date provides a long-term alignment with future company performance.
Industry Context
This is a routine insider transaction, common in the biotechnology industry, where equity compensation is frequently used to attract and retain key directors and executives, aligning their interests with the company's long-term growth and shareholder value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Grant | James Panek granted a Limited Power of Attorney to Regina Cheng, David Pauling, and Gregory Chow to execute and file Forms 3, 4, and 5 on his behalf, ensuring compliance with Section 16(a) of the Securities Exchange Act of 1934. | 2025-10-06 | Streamlines compliance for insider reporting requirements for the director, ensuring timely and accurate filings. |
Stakeholder Impact
- Shareholders: The option grant aligns the director's incentives with shareholder value creation, potentially leading to more focused long-term decision-making.
Next Steps
- The stock options will begin vesting on January 23, 2026, at a rate of 16.67% monthly.
- James P. Panek's continued service to Sutro Biopharma, Inc. is required for the options to vest.
Key Dates
| Date | Description |
|---|---|
| 2025-10-06 | Date James Panek executed the Limited Power of Attorney. |
| 2025-12-23 | Date of earliest transaction (stock option grant). |
| 2025-12-29 | Date the Form 4 was signed by the attorney-in-fact. |
| 2026-01-23 | Date of the first vesting tranche for the stock options. |
| 2035-12-23 | Expiration date of the stock options. |
Keywords
Sutro Biopharma, STRO, Stock Option, Director Compensation, Insider Transaction, SEC Form 4, Equity Grant, Vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.